You can buy or sell Recro Pharma and other stocks, options, ETFs, and crypto commission-free!
Recro Pharma, Inc. Common Stock, also called Recro Pharma, is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. Read More It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company's formulation expertise to develop and manufacture pharmaceutical products using the company's proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.
52 Week High
52 Week Low
Research And Development
Seeking AlphaMay 13
Recro Pharma, Inc. CEO Geraldine Henwood on Q1 2019 Results - Earnings Call Transcript
Recro Pharma, Inc. (NASDAQ:REPH) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Claudia Styslinger - IR Geraldine Henwood - President & CEO Ryan Lake - CFO Conference Call Participants Leland Gershell - Oppenheimer & Co. David Amsellem - Piper Jaffray Scott Henry - Roth Capital Patrick Trucchio - Berenberg Capital Market Operator Good morning, and welcome to the Recro Pharma First Quarter 2019 Financial Results Conference Call. [Operator Instructions] As a reminder,...
Yahoo FinanceMay 10
Recro Pharma Reports First Quarter 2019 Financial Results
Company to Host Conference Call Today at 8:00 AM ET MALVERN, Philadelphia, May 10, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three months ended March 31, 2019. “Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter,” ...
Yahoo FinanceMay 8
Recro Pharma, Inc. (REPH): Here are Midwood Capital Management’s Thoughts On The Pharmaceutical Company
Midwood Capital Management explained recent Recro Pharma (NASDAQ:REPH) stock price fluctuations in its Q1 2019 Investor Letter. If you are interested you can find a copy of the letter here. The fund also disclosed the quarterly return of 10.6%, and an annualized return since inception of 9.5%. "Recro Pharma, Inc. (REPH; $8.36; $184million market cap): We highlighted REPH in our Fourth Quarter 2018 Letter to Investors–when the stock was at $7.91 –believing that one key catalyst would be FDA approval of REPH...
-$1.06 per share
-$0.10 per share